Evidence map›Paper›PMID 42169021›Full record

ArticleBMC endocrine disorders2026

Interplay of BRAF and TERT promoter mutations and Ki67 proliferation index in papillary thyroid carcinoma in Central Asians.

Akbota Targynova, Zhanna Mussazhanova, Andrey Bychkov, Hirokazu Kurohama, Askar Tlegenov, Dauren Adilbay, Zhanar Yeleubayeva, Zaure Dushimova, Tamila Akhayeva, Hisayoshi Kondo and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Akbota TargynovaAl-Farabi Kazakh National University, Almaty, Kazakhstan.
Zhanna MussazhanovaAl-Farabi Kazakh National University, Almaty, Kazakhstan. ghannakz@mail.ru.ORCID http://orcid.org/0000-0002-7315-7725
Andrey BychkovDepartment of Pathology, Kameda Medical Center, Kamogawa, Japan.
Hirokazu KurohamaDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Askar TlegenovAsfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
Dauren AdilbayMedical University South Carolina, Charleston, USA.
Zhanar YeleubayevaKazakh Institute of Oncology and Radiology, Almaty, Kazakhstan.
Zaure DushimovaAl-Farabi Kazakh National University, Almaty, Kazakhstan.
Tamila AkhayevaAl-Farabi Kazakh National University, Almaty, Kazakhstan.
Hisayoshi KondoBiostatistics Section, Division of Scientific Data Registry, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Masahiro NakashimaDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPapillary thyroid carcinoma (PTC) is the most prevalent subtype of thyroid carcinoma, constituting 80-85% of all cases. The clinical challenges posed by PTC are further compounded by its steadily increasing global incidence. Primarily associated with mutations in BRAF V600E and the TERT promoter (TERTp), the aggressive clinicopathological features and poor prognosis of PTC are exacerbated when these mutations co-occur. The Ki67 labeling index (LI), which reflects the proliferation rate of tumor cells, plays a pivotal role in assessing cancer aggressiveness. However, research on mutations in PTC cases in Kazakhstan is limited.

methodsThis retrospective study included 240 patients with PTC. DNA extraction and mutation screening, droplet digital PCR (ddPCR) analysis for BRAF/TERTp mutations and Ki67 immunohistochemistry were performed. Two-sided Fisher's exact test, the Mann-Whitney U test, Kruskal-Wallis test, analysis of variance for nonparametric data were used.

resultsIn Kazakh PTC cases, BRAF V600E was common (68.3%) and aligned with the patterns observed in the Asian population. TERTp mutations co-occurring with BRAF V600E (4.7%) were associated with advanced age, larger tumor size, lymph node metastasis, higher cancer stage, and higher Ki67 LI (10%).

conclusionThis study sheds light on the prevalence of BRAF V600E and TERTp mutations in Kazakhs with PTC. The integration of Ki67 LI assessment and mutation analysis may be instrumental in predicting the aggressiveness of PTC and guiding treatment decisions in this population. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Ki-67 AntigenMutationPromoter Regions, GeneticProto-Oncogene Proteins B-rafTelomeraseThyroid Cancer, PapillaryThyroid NeoplasmsAdultAgedBiomarkers, TumorCell ProliferationFemaleFollow-Up StudiesHumansKazakhstanMaleBiomarkers, TumorBRAF protein, humanKi-67 AntigenProto-Oncogene Proteins B-rafTelomeraseTERT protein, humanBRAF V600E mutationKazakh populationKi67 labeling indexPapillary thyroid carcinomaTERT promoter mutation

Identifiers

PMID42169021
PMCPMC13371233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.